<?xml version="1.0" encoding="UTF-8"?>
<ref id="b11-1031308">
 <label>11.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Martinez-Cuadron</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Boluda</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Martinez</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia</article-title>. 
  <source>Ann Hematol</source>. 
  <year>2018</year>;
  <volume>97</volume>(
  <issue>5</issue>):
  <fpage>763</fpage>â€“
  <lpage>772</lpage>.
  <pub-id pub-id-type="pmid">29392425</pub-id>
 </mixed-citation>
</ref>
